|

Camizestrant Clinical Trials

6 actively recruiting trials across 4 locations

▼ -1 trial since August 2026

Also known as: AZD9833

Pipeline

Phase 2: 2Phase 3: 3Phase 1/2: 1

Top Sponsors

  • AstraZeneca5
  • MedSIR1

Indications

  • Breast Cancer6
  • Cancer6
  • Advanced Breast Cancer2
  • ER-Positive HER2-Negative Breast Cancer1
  • Hormon Receptor Positive Breast Cancer1

St Louis, Missouri2 trials

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Research Site

Phase 1/2
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Research Site

Phase 2

Other1 trial

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
Phase 2

Birmingham, Alabama1 trial

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Research Site

Phase 3

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Duarte, California1 trial

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.